Date: 2013-04-22
Type of information: Fundraising
Company: Curetis (Germany)
Investors: HBM Partners (Cayman Islands) aeris Capital (Switzerland) LSP Life Sciences Partners (The Netherlands) Forbion Capital (The Netherlands) BioMedInvest (Switzerland) Roche Venture Fund (Switzerland) CD Venture (Germany) KfW (Germany) Curetis’ management , several of the company\'s founders, private investors, board members
Amount: € 20 million
Funding type: series B financing round
Planned used: Curetis will use the proceeds for the next phase of commercial and operational growth, including a prospective, multi-center FDA registrational trial with 2,000 patients and the further expansion of the company’s commercial activities and team in Europe. Curetis anticipates a phase of rapid market adoption in the DACH region (Germany, Austria, Switzerland) where more than 50 top tier hospitals have agreed to install Unyvero™ for local testing. The inclusion of Unyvero™ in an upcoming global Phase IIb trial by Sanofi Pasteur is expected to add further momentum to the market penetration of Unyvero™. Moreover, the company expects to continue the rapid international expansion of its commercial distribution network across Europe and the Middle East, but also towards Asia, Latin America and, following FDA clearance, to the USA.
Others: * On April 22, 2013, Curetis has announced the closing of a Series B financing round totaling € 12.5 million. The financing was led by HBM Partners, which has taken a € 6.0 million equity stake in Curetis. Dr. Alexander Asam of HBM will join Curetis’ supervisory board. In addition, the company’s existing institutional investors aeris Capital, LSP Life Sciences Partners, Forbion Capital, BioMedInvest, Roche Venture Fund, CD Venture and KfW have contributed a total of € 5.6 million to the round on a pro rata basis. Curetis’ management as well as several of the company\'s founders, private investors and board members also co-invested. Including the latest Series B financing, Curetis has raised a total of € 49.1 million in equity capital to date.
Further upcoming milestones include the market launch of a second Unyvero™ cartridge application (ITI) together with Heraeus Medical and clinical data from a global Phase III trial in community-acquired bacterial pneumonia conducted by Cempra Pharmaceuticals.
Therapeutic area: Infectious diseases
